ReviewDiagnostics (Basel, Switzerland)2021
Prognostic Value of
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance of 18F-Fluorodeoxyglucose positron-emission tomography parameters in patients with biliary tract cancers: a meta-analysis.BMC medical imaging · 2024Pooled it
- Evaluating the prognostic impact of multipleEuropean journal of nuclear medicine and molecular imaging · 2026Trial
- [18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Baseline ¹BMC cancer · 2026Article
- Utilizing temporal information to assess metabolic heterogeneity: a study ofQuantitative imaging in medicine and surgery · 2025Article
- Predicting response and survival to first-line treatment with baseline [Therapeutic advances in medical oncology · 2025Article
- Primary tumor SUVWiener klinische Wochenschrift · 2023Article
- Article
- Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Article
- Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.Cancers · 2022Review
- PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses.Cancers · 2021Review
- The association of metabolic positron emission tomography/computed tomography parameters with survival in small cell lung cancer.Annals of Saudi medicineArticle
- The impact of radiometabolic features on the stage and survival in small cell lung cancer.Annals of thoracic medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.